213 related articles for article (PubMed ID: 22664112)
1. Treatment of hairy cell leukemia: long-term results in a developing country.
Ruiz-Delgado GJ; Tarín-Arzaga LC; Alarcón-Urdaneta C; Calderón-García J; Gómez-Almaguer D; Ruiz-Argüelles GJ
Hematology; 2012 May; 17(3):140-3. PubMed ID: 22664112
[TBL] [Abstract][Full Text] [Related]
2. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
3. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
4. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
8. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
Hacioglu S; Bilen Y; Eser A; Sivgin S; Gurkan E; Yildirim R; Aydogdu I; Dogu MH; Yilmaz M; Kayikci O; Tombak A; Kuku I; Celebi H; Akay MO; Esen R; Korkmaz S; Keskin A
Hematol Oncol; 2015 Dec; 33(4):192-8. PubMed ID: 25393847
[TBL] [Abstract][Full Text] [Related]
9. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group].
Raemaekers JM; van 't Veer MB; Bogman MJ
Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1600-4. PubMed ID: 8768814
[TBL] [Abstract][Full Text] [Related]
10. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
Chadha P; Rademaker AW; Mendiratta P; Kim B; Evanchuk DM; Hakimian D; Peterson LC; Tallman MS
Blood; 2005 Jul; 106(1):241-6. PubMed ID: 15761021
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hairy-cell leukemia: current views.
Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Hoffman MA; Janson D; Rose E; Rai KR
J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine.
Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M
Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hairy cell leukemia with cladribine].
Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
[TBL] [Abstract][Full Text] [Related]
17. Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients.
Marotta G; Frassoldati A; Zinzani P; Annino L; Brugiatelli M; Ambrosetti A; Lenoci M; Federico M; Foa R; Lauria F;
Eur J Haematol; 2006 Aug; 77(2):109-13. PubMed ID: 16856905
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
19. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
20. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
Robak T; Błasińska-Morawiec M; Krykowski E; Hansz J; Komarnicki M; Kazimierczak M; Konopka L; Maj S; Hellmann A; Zaucha JM; Urasiński L; Zdziarska B; Kotlarek-Haus S; Usnarska-Zubkiewicz L; Kuratowska Z; Dwilewicz-Trojaczek J; Hołowiecki J; Krawczyk-Kulis M; Grieb P
Leuk Lymphoma; 1996 Jun; 22(1-2):107-11. PubMed ID: 8724536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]